TNYA Key Statistics, Chart & Performance
The current stock price of TNYA is 0.8115 USD. In the past month the price increased by 5.12%. In the past year, price decreased by -15.86%.
TNYA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to TNYA. When comparing the yearly performance of all stocks, TNYA is a bad performer in the overall market: 86.94% of all stocks are doing better.
TNYA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TNYA. While TNYA seems to be doing ok healthwise, there are quite some concerns on its profitability.
TNYA Financial Highlights
Over the last trailing twelve months TNYA reported a non-GAAP Earnings per Share(EPS) of -0.78. The EPS increased by 45.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -89.94% | ||
| ROE | -113.94% | ||
| Debt/Equity | 0 |
TNYA Forecast & Estimates
14 analysts have analysed TNYA and the average price target is 9.18 USD. This implies a price increase of 1031.24% is expected in the next year compared to the current price of 0.8115.
TNYA Ownership
TNYA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.39 | 387.092B | ||
| AMGN | AMGEN INC | 17.06 | 198.053B | ||
| GILD | GILEAD SCIENCES INC | 17.07 | 185.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.48 | 116.409B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.91 | 80.573B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.82 | 43.76B | ||
| INSM | INSMED INC | N/A | 32.21B | ||
| NTRA | NATERA INC | N/A | 27.199B | ||
| BIIB | BIOGEN INC | 13.02 | 27.192B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.47 | 20.623B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TNYA
Company Profile
Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. The company is headquartered in South San Francisco, California and currently employs 97 full-time employees. The company went IPO on 2021-07-30. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.
Company Info
TENAYA THERAPEUTICS INC
171 Oyster Point Blvd., Suite 500
South San Francisco CALIFORNIA US
CEO: Faraz Ali
Employees: 97
Phone: 14158652066
TENAYA THERAPEUTICS INC / TNYA FAQ
Can you describe the business of TENAYA THERAPEUTICS INC?
Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. The company is headquartered in South San Francisco, California and currently employs 97 full-time employees. The company went IPO on 2021-07-30. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.
Can you provide the latest stock price for TENAYA THERAPEUTICS INC?
The current stock price of TNYA is 0.8115 USD. The price increased by 8.2% in the last trading session.
Does TENAYA THERAPEUTICS INC pay dividends?
TNYA does not pay a dividend.
What is the ChartMill rating of TENAYA THERAPEUTICS INC stock?
TNYA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists TNYA stock?
TNYA stock is listed on the Nasdaq exchange.
Can you provide the upcoming earnings date for TENAYA THERAPEUTICS INC?
TENAYA THERAPEUTICS INC (TNYA) will report earnings on 2026-03-02, after the market close.
What is the Short Interest ratio of TENAYA THERAPEUTICS INC (TNYA) stock?
The outstanding short interest for TENAYA THERAPEUTICS INC (TNYA) is 14.23% of its float.